|Positive WB detected in||mouse heart tissue, mouse skeletal muscle tissue|
|Positive IP detected in||mouse heart tissue|
|Positive IHC detected in||mouse heart tissue, human heart tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||mouse heart tissue|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
17283-1-AP targets MYL7 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||MYL7 fusion protein Ag11058|
|Full Name||myosin, light chain 7, regulatory|
|Calculated molecular weight||175 aa, 19 kDa|
|Observed molecular weight||19 kDa|
|GenBank accession number||BC027915|
|Gene ID (NCBI)||58498|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
MYL7, also known as myosin light chain 2a (MLC2a), is essential for heart development. The expression of MYL7 in heart is predominatantly restricted to the atrium. So its expression has been considered as useful marker for atrial cardiomyocytes.
|Product Specific Protocols|
|WB protocol for MYL7 antibody 17283-1-AP||Download protocol|
|IHC protocol for MYL7 antibody 17283-1-AP||Download protocol|
|IF protocol for MYL7 antibody 17283-1-AP||Download protocol|
|IP protocol for MYL7 antibody 17283-1-AP||Download protocol|
|Click here to view our Standard Protocols|
High content analysis identifies unique morphological features of reprogrammed cardiomyocytes.
Stem Cell Reports
Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation.
Angiopoietin-1 enhanced myocyte mitosis, engraftment, and the reparability of hiPSC-CMs for treatment of myocardial infarction.
High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling.